News Releases

Tokyo, April 3, 2012, Taiho Pharmaceutical Co., Ltd., announced today that it has received marketing authorization for its anticancer agent TS-1, in Hong Kong. The anticancer agent, developed by Taiho, is already available in Asian countries, which are Japan, South Korea, China, Singapore and Taiwan.

TS-1 has been approved in Hong Kong for post operative adjuvant chemotherapy for locally advanced gastric cancer, and is scheduled to be marketed under the product name TS-ONE_® by the TS-ONE dedicated promotion team of Taiho's local partner, DKSH Holding Ltd..

TS-1 has a wide variety of indications and has helped to extend the lives of numerous patients in Japan since its release in 1999. It is used for the treatment of gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, inoperable or recurrent breast cancer, pancreas and biliary tract cancers. For gastric cancer, TS-1 has become the standard chemotherapy in Japan.

DKSH is the leading Market Expansion Services Group with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. With 650 business locations in 35 countries – 630 of them in Asia – and over 24,000 specialized staff, it is one of the top 20 Swiss companies ranked by sales and employees. In 2011, DKSH generated Net Sales of CHF 7.3 billion. DKSH's Business Unit Healthcare is a leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies. The Business Unit provides a comprehensive portfolio of integrated services ranging from product registration, importation, manufacturing, marketing and sales to distribution, and after-sales. With 150 business locations in 13 countries and over 8,000 specialized staff, Business Unit Healthcare generated Net Sales of CHF 2.9 billion in 2011.